BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12353511)

  • 1. Oophorectomy in carriers of BRCA mutations.
    Peshkin BN; DeMarco TA; Schwartz MD
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353511
    [No Abstract]   [Full Text] [Related]  

  • 2. Oophorectomy in carriers of BRCA mutations.
    Anderson WF; Brawley OW; Chang S
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353512
    [No Abstract]   [Full Text] [Related]  

  • 3. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
    Haber D
    N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
    [No Abstract]   [Full Text] [Related]  

  • 4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oophorectomy in carriers of BRCA mutations.
    Whitfield GA
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353513
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
    Haldar K; Crawford R
    Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk reduction works for BRCA mutation carriers--with heavy costs.
    Vanchieri C
    J Natl Cancer Inst; 2005 Jul; 97(14):1032-3. PubMed ID: 16030299
    [No Abstract]   [Full Text] [Related]  

  • 8. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
    Agnantis NJ; Paraskevaidis E; Roukos D
    Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
    [No Abstract]   [Full Text] [Related]  

  • 10. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 11. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproductive issues for women with BRCA mutations.
    Friedman LC; Kramer RM
    J Natl Cancer Inst Monogr; 2005; (34):83-6. PubMed ID: 15784831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 14. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
    Matloff ET; Barnett RE; Bober SL
    Cancer J; 2009; 15(1):15-8. PubMed ID: 19197168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving surveillance and quality of life of BRCA mutation carriers.
    Loman N; Borg A
    J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
    [No Abstract]   [Full Text] [Related]  

  • 16. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
    Olivier RI; van Beurden M
    Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hereditary breast cancer: treatment and prevention].
    Ejlertsen B; Gerdes AM
    Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.